Antitrombotik berdasarkan skor CHA2DS2-VASc dan skor HAS BLED terhadap pola pengobatan pada pasien stroke iskemik dengan fibrilasi atrium

Authors

  • Rizaldy Taslim Pinzon Duta Wacana University School of Medicine
  • Gusti Ayu Putu Ika Bella Saptaning Astyari Duta Wacana University School of Medicine
  • Lidwina Taringan Duta Wacana University School of Medicine

DOI:

https://doi.org/10.12928/pharmaciana.v7i1.4716

Abstract

Pendahuluan: Stroke yang berhubungan dengan fibrilasi atrium dan kardioemboli cenderung bermanifestasi lebih berat, berisiko tinggi berulang, serta mortalitasnya lebih tinggi. Pemberian antikoagulan lebih dianjurkan pada stroke iskemik dengan fibrilasi atrium sebagai upaya pencegahan, baik primer maupun sekunder. Skor stratifikasi CHA2DS2-VASc digunakan untuk menseleksi pasien pada risiko terkena stroke iskemik untuk pemilihan antitrombotik yang tepat, pada risiko untuk terjadinya perdarahan skor HAS BLED digunakan sehingga dapat mengurangi kekhawatiran dokter dalam menggunakan antikoagulan. Penelitian sebelumnya sangat terbatas sehingga diperlukan penelitian yang lebih mendukung pada penelitian-penelitian sebelumnya.

Tujuan: untuk mengetahui penggunaan antitrombotik berdasarkan pada skor CHA2DS2-VASc dan skor HAS BLED terhadap pola pengobatan pada pasien stroke dengan fibrilasi atrium

Metode: penelitian ini merupakan studi deskriptif dengan rancangan potong lintang (cross sectional). Sampel diperoleh dari stroke registry  dan rekam medis dari pasien di Poli Saraf  Rumah Sakit Bethesda Yogyakarta pada tahun 2009-2016. Data dianalisis menggunakan analisis univariat.

Hasil: data diperoleh dari 77 pasien stroke iskemik dengan fibrilasi atrium yang terdiri dari 33 laki-laki (42.8%)  dan 44 perempuan (57.1%), proporsi terbesar ada pada pasien berusia >70 tahun (33.3%). Hasil analisis univariat menunjukkan bahwa penggunaan antiplatelet ada pada 71 (92.2%) pasien, penggunan antikoagulan 6 (7.7%) pasien, serta nilai skor CHA2DS2-VASc 0=3 (3.8%), 1=18 (22.5%), ≥2=56 (70.1%), pada skor HAS BLED 0=7 (8.8%), 1=27 (33.8%), 2=29 (36.3%), 3=13 (16.3%), 4=1 (1.3%)

Kesimpulan   : skor CHA2DS2-VASc dan skor HAS BLED belum mempengaruhi penggunaan antitrombotik pada pasien stroke iskemik dengan fibrilasi atrium di RS Bethesda Yagyakarta

Kata Kunci    : Stroke iskemik, skor CHA2DS2-VASc, skor HAS BLED, Fibrilasi atrium.


 

References

Shahpouri, M., Mousavi, S., Khorvash, F., et al. (2012) Anticoagulant therapy for ischemic stroke: A review of literature. J Res Med 17 (4). PP 396-401.

Singer, D.E., Albers, G.W., Dalen, J.E., et al. (2008) Antithrombotic therapy in atrial fibrillation. 8th Edition. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. PP 396-401.

Isla M.O.,Nick N.,Sharon A.W.,Warren C.,Gregory Y.H.(2009) Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review; BioMedCom Consultants Inc., Montréal, Canada;Global Health Economics and Reimbursement, Bayer HealthCare, Uxbridge,

Olesen, J.B., Fauchier, L., Lane, D.A., Taillandier, S., Lip, G.Y. (2012) Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project (141). PP 147-53.

Gallego, P., Roldan, V., Torregrosa, J.M., et al. (2012) Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation: Journal of circulation Arrhythmia and electrophysiology (5). PP 312-8.

Olesen, J.B., Fauchier, L., Lane, D.A., Taillandier, S., Lip, G.Y. (2012) Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation. The Loire Valley Atrial Fibrillation Project (141). PP 147-53.

Leithäuser B, Jung F, Park J-W, (2013) Oral anticoagulation for prevention of cardioembolic stroke in patients with atrial fi brillation: Focusing the elderly. Applied Cardiopulmonary Pathophysiology.

Gallego, P., Roldan, V., Torregrosa, J.M., et al. (2012) Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation: Journal of circulation Arrhythmia and electrophysiology (5). PP 312-8.

Singer, D.E., Albers, G.W., Dalen, J.E., et al. (2008) Antithrombotic therapy in atrial fibrillation. 8th Edition. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. PP 396-401.

Ka L.W., YilongW., XinyiL., et al. (2013) Early Dual Versus Mono Antiplatelet Therapy for Acute Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack, An Updated Systematic Review and Meta-Analysis. AHA journal 128:1656-1666.

Intercollegiate Stroke Working Party, (2012) National clinical guideline for stroke 4th ed. Royal college of physician.

Isla M.O.,Nick N.,Sharon A.W.,Warren C.,Gregory Y.H.(2009) Underuse of Oral Anticoagulants in Atrial Fibrillation: A Systematic Review; BioMedCom Consultants Inc., Montréal, Canada;Global Health Economics and Reimbursement, Bayer HealthCare, Uxbridge.

Downloads

Published

2017-05-08

Issue

Vol. 7 No. 1 (2017): Pharmaciana

Section

Clinical and Community Pharmacy

License

Authors who publish with Pharmaciana agree to the following terms:

  1. Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.